Q&A with Dr Alexandre Akoulitchev Chief Scientific Officer at Oxford Biodynamics PLC (LON:OBD)

Oxford Biodynamics PLC (LON:OBD) Chief Scientific Officer Dr Alexandre Akoulitchev caught up with DirectorsTalk for an exclusive interview to discuss their latest ALS biomarker data


Q1: The latest results presented at Boston CNS World Summit are based on extensive biomarker analysis, multi-centre studies and large patient cohorts, some of them observed repeatedly over a period of 3 and 6 months. Can you tell us more on how Oxford Biodynamics’ work aligns itself with the ALS field, key clinical specialists and institutions?

A1: The results that were presented in Boston is actually a follow-up of very extensive work with several key leaders in the field and very successful results built on a very successful collaboration. We’ve been engaged from the very beginning with Massachusetts General Hospital and Chief of Neurology, Professor Merit Cudkowicz and with the very generous support from Innovate UK, we extended our work in the UK with the University of Oxford, the Nuffield Department of Clinical Neurosciences, Professor Kevin Talbot. In fact, ended up working the three centres in the States, the UK and also in Malaysia where we have a separate subsidiary with the University Hospital Malaya, Professor Goh Khean Jin. All uniquely substantial cohorts of patients, both Caucasian and Asian, and a lot of credit should go to help in guidance, collaboration and clinical expertise.


Q2: Now, the FDA has approved only two drugs for ALS, Riluzole from Sanofi and Radicava from Mitsubishi Tanabe, how would your biomarker work help in more successes in therapeutic developments for ALS?

A2: ALS proves to be a very difficult disease with a lot of failures in clinical development and what we do answers very particular questions relevant from drug development, in particular not only the early pre-symptomatic detection of the disease but also the prognostic stratification so that one can populate a trial, include the right patients early with fast-progressing ALS.

There is multiple evidence that we might be dealing with subtypes within the disease. Our readouts on biomarker platforms are picking systemic and genetic differences. It might be a very valuable addition to all joint efforts today to try to understand the subtypes and match potential treatments, treatments in development with the right sub group of patients.


Q3: The biomarker approach that Oxford Biodynamics has developed and the examples of your applications, how useful is it to other actionable patient stratifications in neurogenerative and neuropsychiatric conditions?

A3: It is very relevant, and we are very glad that, first of all, we’re were able to build up and present evidence within ALS taking some of the signatures for validation already but also the field itself has been paying very close attention to genome architecture, chromosome conformation signatures, all the modalities we’re working with.

Within the peer group space, there is significant evidence that our platform, our operation, would be very applicable to such diseases as Alzheimer’s, Multiple Sclerosis, many other neurogenerative conditions, autism, post-traumatic stress disorder, depression.

The very nature of what we do and what we measure brings out readouts based on blood so we’re dealing with liquid biopsy, non-invasive results, which from a clinical practice point of view, it’s particularly valuable today.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,

    Oxford BioDynamics

    New questions about Covid-19

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more at risk,

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities such as

    Oxford BioDynamics

    ALS Awareness

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in response to

    Oxford BioDynamics

    ALS Awareness Month This May

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated the letters

    Oxford BioDynamics

    Microarray Facility

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of multiplex formats

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that integrate environmental

    No more posts to show